In ovarian cancer, Scalici et al. [77] showed significant increase in VCAM-1 expression with advancing tumour stage and its expression was found to reduce in patients who received neoadjuvant chemotherapy while, in a study by Huang et al. [75], the overexpression of VCAM-1 was associated with advanced age at diagnosis as well as with response to treatment with surgery and chemotherapy. This evidence concerns the gene VCAM1 and neoplasm.